Rofecoxib: A specific cyclooxygenase inhibitor

Drugs of Today

Volumn 36, Issue 4, 2000, Pages 255-262

  Cannon, Grant W ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE B2;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG MECHANISM; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; TOOTH PAIN;

EID: 0034028788     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.4.570204     Document Type: Review

References (39)

1. Hawkey, C.J. COX-2 inhibitors. Lancet 1999, 353: 307-14.
2. Jouzeau, J.Y., Terlain, B., Abid, A., Nedelec, E., Netter, P. Cyclo-oxygenase isoenzymes. Drugs 1997, 53: 563-82.
3. Needleman, P., Isakson, P.C. The discovery and function of COX-2. J Rheumatol 1997, 24(Suppl. 49): 6-8.
4. Crofford, J. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997, 24: 1519.
5. Bjorkman, D.J. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998, 105(1B): 8-12S.
6. Breder, C.D., DeWitt, D.L., Kraig, R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995, 355: 196-315.
7. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971, 231: 232-5.
8. Vane, J.R., Botting, R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104(4A): 2-22S.
9. Fries, J.R, Williams, C.A., Bloch, D.A. et al. NSAID associated gastropathy: Incidence and risk factor models. Am J Med 1991, 912: 213-21.
10. Griffen, M.R., Piper, J.M., Daugherty, J.R. et al. NSAID use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114: 257-63.
11. Chan, C.C., Boyce, S., Brideau, C. et al. Rofecoxib [Vioxx, MK-0966: 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanonel]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999, 290: 551-60.
12. ™ prescribing information. Merck & Co., Inc., New Jersey 1998.
13. Chan, C.C., Boyce, S., Brideau, C. et al. Pharmacology of a selective cyclooxygenase-2-inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non human primates stomach. J Pharmacol Exp Ther 1995, 274: 1531-7.
14. Van Hecken, A., Depré, M., Ehrich, E. et al. Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherarpeutic doses. Clin Pharmacol Ther 1999, 65: 164.
15. Catella-Lawson, F., McAdam, B., Morrison, B.W. et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289: 735-41.
16. 2) synthesis in healthy humans. Gastroenterology 1999, 116(4): A141.
17. Ehrich, E.W., Dallob, A., Lepeleire, I.D. et al. Characterization of rofecoxib as cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999, 65: 336-47.
18. Ehrich, E.W., Schnitzer, T.J., Mcllwin, H. et al. Effect of specific COX-2 inhibitor in osteoarthritis of the knee: A 6-week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999, 26: 2438-47.
19. Ehrich, E., Schnitzer, T., Kivitz, A. et al. MK-0966, a highly selective COX-2 inhibitor was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1997, 40(Suppl.): 330.
20. Saag, K., Fisher, C., McKay, J. et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. Arthritis Rheum 1998, 41(Suppl.): S196.
21. Daniels, B., Krupa, D., Ehrich, E., Bolognese, J., Seidenberg, B. Clinical response of OA patients who use acetaminophen when randomized to rofecoxib or ibuprofen. Arthritis Rheum 1999, 42(Suppl.): S143.
22. Cannon, G., Caldwell, J., Holt, P. et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum 1998, 41(Suppl.): S196.
23. Geba, G.P., Polis, A.B., Dixon, M.E. et al. Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis. Arthritis Rheum 1999, 42(Suppl.): S144.
24. Schnitzer, T.J., Truitt, K., Fleischmann, R. et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999, 21: 1688-702.
25. Reicin, A.S., Brown, J., Jove, M., de Andrade, R.J., Watlers, D., Krupa, D.A. The COX-2 specific inhibitor, rofecoxib, was effective in the treatment of postorthopedic surgical pain. Arthritis Rheum 1999, 42(Suppl.): S268.
26. Morrison, B.W., Christensen, S., Yuan, W., Brown, J., Amlani, S., Seidenberg, B. Analgesic efficacy of the cyclooxgenase-2 specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther 1999, 21: 943-53.
27. Morrison, B.W., Daniels, S.E., Kotey, P., Cantu, N., Seidenberg, B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol 1999, 94: 504-8.
28. Malmstrom, I.K., Daniels, S., Kotey, P., Seidenberg, B.C., Desjardins, P.J. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo-and active-comparator controlled clinical trial. Clin Ther 1999, 21: 1653-62.
29. Fricke, J., Morrison, B.W., Fite, S. et al. MK-966 versus naproxen sodium 550 mg in post-surgical dental pain. Clin Pharmacol Ther 1999, 65: 119.
30. Schwartz, J.I., Chan, C.C., Mukhopadhyay, S. et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 1999, 65: 653-60.
31. Lanza, F.L., Rack, M.F., Simon, T.J. et al. Specific inhibition of cyclooxygenase-2 with MK-966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999, 13: 761-7.
32. Bjarnason, I., Sigthorsson, G., Crane, R. et al. COX-2 specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg tid. Am J Gastroenterol 1998, 93: 1670.
33. Hunt, R., Bown, B., James, C. et al. COX-2 specific inhibition with MK-0966 25 or 50 mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg tid. Am J Gastroenterol 1998, 93: 1671.
34. Laine, L., Harper, S., Simon, T. et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritics. Gastroenterology 1999, 117: 776-83.
35. Laine, L., Hawkey, C., Harper, S. et al. No evidence of H. pylori-NSAID interaction in ulcer formation: Results of double-blind, placebo-controlled trials. Gastroenterology 1999, 116(4): A228.
36. Watson, D.J., Harper, S., Zhao, P., Bolognese, J., Simon, T., Sidenberg, B. Treatment with rofecoxib requires less gastrointestinal (GI) comedication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 1999, 42(Suppl.): S403.
37. Langman, M., Jensen, D., Harper, S. et al. Lower incidence of clinically evident upper-GI perforations, ulcers and bleeds in patients treated with rofecoxib vs. nonspecific cyclooxygenase inhibitors. Gastroenterology 1999, 116(4): A232.
38. Daniels, B., Seidenberg, B. Cardiovascular safety profile of rofecoxib in controlled clinical trials. Arthritis Rheum 1999, 42(Suppl.): S143.
39. Daniels, B., Gertz, B., Morrison, B., Seidenberg, B. Renal safety profile of rofecoxib, a specific inhibitor of COX-2 in controlled clinical trials. Arthritis Rheum 1999, 42(Suppl.): S143.